Hensley, M. L., Blessing, J. A., Mannel, R., & Rose, P. G. (2008). Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial.
Chicago-stil citatHensley, Martee L., John A. Blessing, Robert Mannel, och Peter G. Rose. Fixed-dose Rate Gemcitabine Plus Docetaxel As First-line Therapy for Metastatic Uterine Leiomyosarcoma: A Gynecologic Oncology Group Phase II Trial. 2008.
MLA-referensHensley, Martee L., John A. Blessing, Robert Mannel, och Peter G. Rose. Fixed-dose Rate Gemcitabine Plus Docetaxel As First-line Therapy for Metastatic Uterine Leiomyosarcoma: A Gynecologic Oncology Group Phase II Trial. 2008.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.